Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

What Was Tested

The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in the context of sleep apnea (obstructive), published as a randomized controlled trial.

Tirzepatide may be a potential treatment.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The researchers conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity.

Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.

Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure.

What Was Measured

PubMed files the paper under topics including Blood Pressure, C-Reactive Protein, Hypoxia, Obesity, Sleep Apnea, Obstructive, Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in people with sleep apnea (obstructive).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (The New England journal of medicine), a journal based in United States.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, Sleep apnea (obstructive) research.